Covid-19: China Says Its Vaccine Gets Into 3rd Phase of Clinical Trails

SRINAGAR: A Chinese biotechnology firm has devised an inactivated Covid-19 vaccine candidate which has been proved safe and tolerable and can induce a quick immune response, Chinese official news agency Xinhua reported. The findings from the vaccine candidates early and mid-stage clinical trials were published in the journal The Lancet Infectious Diseases.

A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd., in Beijing, capital of China. Pic: Internet

“The level of antibodies induced by the vaccine was lower than those in people who had recovered from Covid-19, whereas it was capable of protecting the human body from infections caused by the virus,” the agency quoted the findings said.

The vaccine, CoronaVac, was developed by a Chinese biopharmaceutical producer Sinovac Biotech.

It was tested in randomized, double-blind and placebo-controlled phase-1 and phase-2 clinical trials involving more than 700 healthy adults aged 18 to 59.

Vaccination is done with two doses taken 14 days apart, and the vaccine candidate is effective, which makes it suitable for emergency use amid the pandemic, said Zhu Fengcai, one of the authors of the findings was quoted saying.

Zhu added that further research is needed to verify the duration of the immune response induced by the vaccination.

At present, the vaccine candidate is undergoing phase-3 clinical trials to confirm its effectiveness.

LEAVE A REPLY

Please enter your comment!
Please enter your name here